Clinical research (research involving human subjects) may include the evaluation of therapies, treatments, devices, medications, surgeries, and/or diagnostic tools. The results from clinical research advance the efficacy and safety of new treatments and directly improve patient care and quality of life.

The Division of Infectious Diseases has a research team whom coordinates all clinical research with the Infectious Diseases clinical faculty. In addition to clinical research, the faculty members conduct laboratory research both at the UC Davis Medical Center and on the UC Davis Campus

Each type of clinical research plays an integral part in strengthening our knowledge of certain diseases or conditions. With clinical research, we can implement better techniques to diagnose, treat, and prevent human diseases and conditions.

Clinical Trials

The majority of clinical research consists of clinical trials, which may be sponsored or funded by physicians, foundations, federal health agencies (such as the National Institutes of Health), pharmaceutical companies, or university grants.

A clinical trial is a study that looks for new ways to prevent, detect, diagnose, and/or treat a disease or condition. Clinical trials are research projects that have two main objectives in mind: patient safety and disease treatment/prevention. Patients are at the forefront of medicine when they choose to be a participant in a clinical trial. Not only are they contributing to the medical and scientific understanding of their disease, but they also have access to the newest treatments.

Observational Study

This type of study observes people or specific outcomes are measured and recorded. Clinical data is typically only collected and there isn’t any experimental treatment. Another term for these types of studies are retrospective reviews or registry study. 

These studies help us understand specific diseases and to identify any causal relationships. Participating in these studies provide important information that has the possibility to help future patients.

Basic Research

These studies collect biological samples from volunteers who are either healthy or suffer from a specific condition. Subjects typically do not directly benefit from participation but their participation has the possibility to help future patients.

Clinical research studies are very different from regular medical care. Your primary care physician will diagnose and treat you for an illness or condition. Clinical researchers gather new information to help improve future medical care.

For additional information, contact the research team at hs-IDresearch@ucdavis.edu

Study TitleA Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study to Evaluate The Efficacy, Safety and Tolerability of a Clostridium difficile Vaccine in Adults 50 Years of Age and Older

  • Study Type: Phase 3, observer-blinded
  • Purpose: To demonstrate that the vaccine is effective in reducing the incidence of Clostridium difficile.
  • Principal Investigator: Stuart Cohen, MD
  • Study Contact: Jackie Maya-Silva —ph: 916-734-8330 email: jmaya@ucdavis.edu

Study TitleA Phase 3, Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection

  • Study Type: Phase 3, double-blinded
  • Purpose: To confirm the efficacy and safety of the study drug in preventiing reccurent Clostridium difficile.
  • Principal Investigator: Stuart Cohen, MD
  • Study Contact: Carlos Figueroa —ph: 916-734-8101 email: cfigueroa@ucdavis.edu

Study Title: A Phase 3 Multicenter, RandomizeEd, Double Blind, -Placebo Controlled, -Parallel Group- Study to Evaluate the Safety, Tolerability, and Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium difficile Infection (CDI) in Adults Who Have Received Antibacterial Drug Treatment for Recurrent CDI (RCDI)

  • Study Type: Phase 3, double-blinded
  • Purpose: To demonstrate the safety and efficacy of the study drug in reducing Clostridium difficile infection (CDI) recurrence rates.
  • Principal Investigator: Stuart Cohen, MD
  • Study Contact: Lena Stashko —ph: 916-734-5174 email: lstashko@ucdavis.edu

Study TitleAn Open-Label Extension of Study SERES 0012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection 

  • Study Type: Phase 3, open-label
  • Purpose: The purpose of this study is to assess safety and efficacy of the study drug in reducing recurrence of Clostridium difficile infection (CDI) in adults who had a CDI recurrence in parent study.
  • Principal Investigator: Stuart Cohen, MD
  • Study Contact: Lena Stashko —ph: 916-734-5174 email: lstashko@ucdavis.edu

Study Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients

  • Study Type: Phase 3, double-blinded
  • Purpose: To prevent CMV disease in donor positive, recipient negative kidney transplant recipients.
  • Principal Investigator: Stuart Cohen, MD
  • Study Contact: Lena Stashko —ph: 916-734-5176 email: lstashko@ucdavis.edu

Study Title: A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

  • Study Type: Phase 3, open-label
  • Purpose: To compare the efficacy of study drug to standard of care on CMV viremia clearance and tissue-invasive CMV disease.
  • Principal Investigator: Stuart Cohen, MD
  • Study Contact: Kate Trigg —ph: 916-734-8033 email: ktrigg@ucdavis.edu

Study Title: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are at Risk of HIV-1 Infection

  • Study Type: Phase 3, double-blind
  • Purpose: To see if F/TAF is safe and effective for use as pre-exposure Prophylaxis (to prevent) or PrEP to prevent HIV-1 infection in healthy adults.
  • Principal Investigator: David Asmuth, MD
  • Study Contacts: Tammy Yotter, RN at 916-914-6261

Study Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects who are Virologically Suppressed

  • Study Type: Phase 3, double-blind
  • Purpose:
  • Principal Investigator: Richard Pollard, MD
  • Study Contact: Sarah Benedetti —ph: 916-914-6319 email: smbenedetti@ucdavis.edu

Study Title: A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of CD101 Injection vs Intravenous Caspofungin Followed by Oral Fluconazole Step-down in the Treatment of Subjects with Candidemia and or Invasive Candidiasis

  • Study Type: Phase 2, double-blind
  • Purpose: The purpose of this study is to evaluate the safety, tolerability and overall success of CD101 in subjects with candidemia and/or invasive candidiasis. 
  • Principal Investigator: George Thompson, MD
  • Study Contact: Kate Trigg —ph: 916-734-8033 email: ktrigg@ucdavis.edu

Study Title: Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients with Fungal Diseases that are Refractory to or Intolerant of Standard Antifungal Treatment

  • Study Type: Open-label
  • Purpose: The purpose of this study is to evaluate the safety and efficacy of the study drug by assessing global success at the end of treatment. 
  • Principal Investigator: George Thompson, MD
  • Study Contact: Carlos Figueroa —ph: 916-734-8101 email: cfigueroa@ucdavis.edu

Study Title: A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults with Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients

  • Study Type: Phase 2, open-label
  • Purpose: The purpose of this study is to compare the safety and efficacy of the study drug to standard of care treatment of invasive aspergillosis. 
  • Principal Investigator: George Thompson, MD
  • Study Contact: Kate Trigg —ph: 916-734-8033 email: ktrigg@ucdavis.edu

Study Title: A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis caused by a Non-fumigatus Species

  • Study Type: Observational study
  • Purpose: The purpose of this study is to evaluate subjects who received systemic antifungal therapy for the treatment of invasive mucormycosis or invasive aspergillosis. 
  • Principal Investigator: George Thompson, MD
  • Study Contact: Jackie Maya-Silva —ph: 916-734-8033 email: jmaya@ucdavis.edu

Study Title: Observational Disease Registry of Patients Treated with Systemic Mold-Active Triazoles

  • Study Type: Observational study
  • Purpose: The purpose of this study is to describe management patterns of invasive fungal infections with the use of mold-active triazole antifungal therapy.
  • Principal Investigator: George Thompson, MD
  • Study Contact: Carlos Figueroa —ph: 916-734-8101 email: cfigueroa@ucdavis.edu

Study Title: False Positive Serologic Results attributable to IVIG therapy

  • Study Type: Basic Research, serological assessment
  • Purpose: To examine the complications (serologic diagnosis(es)) that can result from IVIG therapy.
  • Principal Investigator: George Thompson, MD
  • Study Contact: Kate Trigg —ph: 916-734-8033 email: ktrigg@ucdavis.edu

Study Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia

  • Study Type: Phase 3, double-blind
  • Purpose: The primary objective of this study is to compare the incidence rate of all-cause mortality of IMI/REL to PIP/TAZ in subjects diagnosed with HABP/VABP (Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia).
  • Principal Investigator: Hien Nguyen, MD
  • Study Contact: Kate Trigg —ph: 916-734-8033 email: ktrigg@ucdavis.edu

Study Title: Dalvance Utilization Registry: A Multicenter, Retrospective Cohort Study to Characterize the Use of Dalvance

  • Study Type: Observational
  • Purpose: To determine patient, disease and pathogen characteristics in patients who received IV Dalvance.
  • Principal Investigator: Hien Nguyen, MD
  • Study Contact: Jackie Maya-Silva – ph: 916-734-8330 email: jmaya@ucdavis.edu